Welcome to the fourth of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?” Transactions involving digital assets are becoming an increasing focus for pharmaceutical companies. In this series, life sciences industry M&A veteran and Sterling Technology board advisor John Easton discusses how these differ from traditional life science deals, and what both parties should look out for to increase the chances of deal success, mitigate risks, and avoid failure.
Technology targets will likely present challenges to dealmakers who are more comfortable evaluating traditional in-licensing or acquisition transactions with pharmaceutical or biotech targets. How should acquirors successfully conduct due diligence on digital assets and what capabilities do they need? Find out by listening to our latest episode. You can also learn more by downloading our report which accompanies this podcast series.
